In his weekly clinical update, Dr. Griffin discusses wastewater surveillance data as a complement to emergency department visit data for tracking the incidence of influenza A and RSV, chatbot-delivered online intervention to promote seasonal Influenza vaccination during the COVID-19 pandemic, temporal assessment of disparities in California COVID-19 mortality by industry, modeling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City, can high COVID-19 vaccination rates in adults help protect unvaccinated children, Nirmatrelvir/Ritonavir use and hospitalizations or death in previously uninfected non-hospitalized high-risk population with COVID-19, Optimal duration of systemic corticosteroids in COVID-19 treatment, and vaccination after developing long COVID.

In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.

In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with COVID-19, and long-term survival after intensive care for COVID-19.

In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Cmmittee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.

TWiV reviews evidence that symptomatic adenovirus infection leads to thrombocytopenia, thrombosis, and production of anti-platelet factor 4 antibodies similar to the rare disorder seen after immunization with adenoviral vectored COVID-19 vaccines, and a monoclonal antibody isolated from a SARS survivor, following vaccination with a SARS-CoV-2 spike mRNA vaccine, that neutralizes a broad collection of ACE2-binding sarbecoviruses..